Formic Ventures
VC Fund
San Francisco, United States
Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Formic Ventures invests in
Stages Formic Ventures invests in
Countries Formic Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.3M–$12M
- Series A
- $17M–$61M
Investment Focus
Industry
- Biotechnology 19 (42%)
- Health Care 13 (29%)
- Pharmaceutical 7 (16%)
- Biopharma 6 (13%)
- Medical 5 (11%)
Stage
- Seed 19 (42%)
- Series A 6 (13%)
- Venture - Series Unknown 4 (9%)
- Series B 3 (7%)
- Pre-Seed 2 (4%)
Country
- United States 24 (53%)
- United Kingdom 3 (7%)
- Hong Kong 2 (4%)
- Canada 1 (2%)
- Isle of Man 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Matt Shlosberg
Chief of Staff
|
Chief of Staff | Total investments: 0 | Find email | |
Michael Antonov
Founder
|
Founder | Total investments: 11 | Find email | |
|
Michael Antonov
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Clinical research platform tailored towards industry sponsors, clinical research sites & patients | $250K / Pre-Seed / Oct 02, 2023 | ||
| SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $60.8M / Series A / Dec 05, 2022 | ||
| CheMastery is a company that creates laboratory automation technology. They provide automation solutions for chemical laboratories in order to facilitate the manufacturing and R&D processes in the chemical sector. It makes science more effective and reliable for scientists in the chemical sector. | Seed / Nov 13, 2022 | ||
| Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work. | $17M / Series A / Sep 07, 2022 | ||
| Nanome is a virtual reality software company that offers a collaborative XR software platform for molecular design.The platform accelerates existing computational workflows at the molecular scale and unlocks more scientists to leverage powerful molecular computations + AI. Nanome has worked largely on projects with companies in the food andbeverage industry, as well as another to develop more sustainable batteries.The San Diego, California-based company was launched in 2015 by Edgardo Leija, Samuel Hessenauer, Keita Funakawa, and Steven McCloskey. | $3.1M / Venture - Series Unknown / Aug 01, 2022 | ||
| Solving cancer resistance. | $12M / Seed / Jul 04, 2022 | ||
| The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS. | $2M / Seed / Apr 12, 2022 | ||
| Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation ofcellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells. | Venture - Series Unknown / Apr 11, 2022 | ||
| Aviron Interactive is a fitness company offering a rower with gamification features. It is a connected rowing machine designed with the user in mind. Short, high-intensity workouts save time, high resistance settings allow to include strength training along with cardio workout, and hundreds of content options to get motivated and keep engaged monthafter month. | $18.6M / Series A / Feb 23, 2022 | ||
| Aviron Ltd engages in the research and development of specific antiviral agents against chronic Hepatitis C Virus (HCV) infection. The company has strategic alliances with CHEMRAR Hi-Tech Center, Chemical Diversity Research Institute, and DRUGS TECHNOLOGY, Ltd. Aviron Ltd was founded in 2010 and is based in Moscow, Russian Federation. | $18.5M / Series A / Feb 23, 2022 | ||
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Formic Ventures invest in?
Formic Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Formic Ventures's check size?
Formic Ventures typically joins rounds of $1.3M–$12M at Seed and $17M–$61M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Formic Ventures participates in.
How do I contact Formic Ventures?
Public channels for Formic Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Formic Ventures?
The team at Formic Ventures includes Matt Shlosberg (Chief of Staff), Michael Antonov (Founder) and Michael Antonov (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
